Nabavka imunoglobulina i vakcina

This tender for immunoglobulins and vaccines by Rakvere Haigla is heavily price-driven, making cost competitiveness paramount. Bidders must demonstrate robust supply chain capabilities and strict adherence to technical specifications to secure this contract. While social value and innovation are not explicitly required, a focus on reliability and product availability will be key differentiators.

Uncompromising Price Competitiveness for Essential Medicines

Guaranteed Supply Chain Reliability and Product Availability

Seamless Compliance with Technical and Regulatory Standards

Achieve the absolute lowest possible price by optimizing all cost components. Conduct a granular cost breakdown and identify areas for efficiency gains. Ensure pricing is competitive but sustainable, reflecting true cost and a lean operational model.

Given the 100% weighting of price, the core strategy must be to submit the lowest possible bid price that is still sustainable. This requires a deep dive into cost structures, supply chain efficiencies, and potential volume discounts from manufacturers. Every effort should be made to undercut competitors on price.

Meticulously review and adhere to all technical specifications and the detailed price offer form. Any deviation or incomplete information can lead to disqualification. Double-check all data fields for accuracy and completeness.

While price is king, demonstrating a robust and reliable supply chain that can consistently meet demand, acting as both primary and secondary supplier, will build confidence. Highlight inventory management systems, logistics networks, and contingency plans.

Ensure strict adherence to all mandatory exclusion grounds (e.g., no Russian/Belarusian ties) and eligibility requirements (e.g., sales permits, non-sanctioned goods). A dedicated compliance check is essential.

While not a primary evaluation factor, acknowledge the contracting authority's right to procure analogues. Frame your bid to emphasize the quality, reliability, and suitability of your primary offerings, implicitly reducing the need for them to seek alternatives.

This tender for immunoglobulins and vaccines is generally well-structured with clear financial information and a reasonable timeline. However, it lacks explicit details on contract duration and evaluation criteria beyond price, and has limited sustainability considerations.

The tender adheres to general procurement regulations, including proper CPV codes and a clear procedure. Deadlines appear reasonable. The exclusion of bidders from Russia and Belarus is a standard geopolitical measure. No disputes are noted. The procedure type 'A' is not fully defined in the provided text, which could be a minor point of ambiguity.

The description of the procurement is clear, outlining the purchase of specific medical supplies for one year. Technical specifications and price offer forms are referenced as separate documents, implying detailed requirements are available. The conditions for rejecting bids and purchasing analogues are also clearly stated.

Most basic information is present, including title, reference, organization, estimated value, and deadlines. However, the contract duration is stated as '1 (üheks) aastaks' in the description but not explicitly in a dedicated 'contract duration' field, and the 'Tender Valid' is 3 months, which is distinct from contract duration. Key documents like technical specifications and contract drafts are mentioned but not fully detailed in the summary.

The tender allows for electronic submission and e-procurement. The estimated value is disclosed. The primary evaluation criterion being the lowest bid price promotes fairness. The ability to purchase analogues for patient-specific needs is a reasonable flexibility. The exclusion of specific countries is a geopolitical requirement, not company-specific tailoring. The framework agreement with up to two bidders is a common and fair practice.

Electronic submission and e-procurement are confirmed. The opening place is a URL to the e-procurement portal. The contract start date is not explicitly stated, which is a common omission but impacts immediate planning. Financing information is not detailed. The duration is mentioned as one year in the description.

Key fields such as title, reference, organization, estimated value, and deadlines are populated. There are no reported suspensions or disputes. Dates provided (Reveal, Submission, Opening) are logically sequential. The 'Tender Valid' period of 3 months is consistent with typical tender processes.

There is no explicit mention of green procurement, social aspects, or innovation in the tender documents. The tender is not indicated as EU funded. This area is largely unaddressed.